Table 2.
Patient characteristics.
| All N = 59 | 2yrS N = 43 | 2yrD N = 16 | P value | |
|---|---|---|---|---|
| Age [years]a | 56 (19–78) | 54 (19–75) | 61 (31–78) | 0.063 |
| Sex [n]b | ||||
| Male:female | 40:19 (68:32) | 27:16 (63:37) | 13:3 (81:19) | |
| Disease [n]b | 0.715 | |||
| Myeloidc | 46 (78) | 34 (79) | 12 (75) | |
| Lymphaticd | 15 (22) | 9 (21) | 4 (25) | |
| Remission at alloHCT [n]b | 0.591 | |||
| CR/chronic phase | 27 (46) | 23 (54) | 4 (25) | |
| Not in CR | 32 (54) | 20 (46) | 12 (75) | |
| HLA-mismatch [n]b | 0.650 | |||
| None (10/10) | 36 (61) | 27 (62.8) | 9 (56.3) | |
| Mismatch (≤9/10) | 23 (39) | 16 (37.2) | 7 (43.8) | |
| Gender donor: recipient | 0.964 | |||
| Female:male | 15 (25) | 11 (26) | 4 (25) | |
| All other | 44 (75) | 32 (74) | 12 (75) | |
| Conditioning [n]b | 0.168 | |||
| Myeloablative | 15 (25.4) | 12 (27.9) | 3 (18.8) | |
| TT/BU/FLU | 12 (20.3) | 9 (21) | 3 (18.8) | |
| TBI/VP16 | 1 (1.7) | 1 (2.3) | 0 | |
| TBI/TT | 1 (1.7) | 1 (2.3) | 0 | |
| FLU/BU 4 | 1 (1.7) | 1 (2.3) | 0 | |
| Reduced intensity | 44 (74.6) | 31 (72.1) | 13 (81.2) | |
| FLU/BCNU/MEL | 14 (23.7) | 10 (23.3) | 4 (25) | |
| FLU/BCNU/TT | 1 (1.7) | 1 (2.3) | 0 | |
| FLU/TT/MEL | 28 (47.5) | 20 (46.5) | 8 (50) | |
| FLU/TT mod. + TREOS | 1 (1.7) | 0 | 1 (6.2) | |
| Time diagnosis to alloHCT [days]a | 214 (51–2569) | 187 (51–2569) | 550 (85–1702) | 0.068 |
| KPS [%]a | 90 (70–100) | 90 (70–100) | 90 (70–100) | 0.375 |
| HCT-CI [n]b | 0.550 | |||
| Low risk (0) | 17 (29) | 13 (30) | 4 (25) | |
| Intermediate risk (1–2) | 20 (34) | 15 (35) | 5 (31) | |
| High risk (≥3) | 22 (37) | 15 (35) | 7 (44) | |
| EBMT score [n]b | 0.768 | |||
| Low risk (0–2) | 7 (12) | 5 (12) | 2 (13) | |
| Intermediate risk (3–5) | 36 (61) | 27 (63) | 9 (56) | |
| High risk (6–7) | 16 (27) | 11 (25) | 5 (31) | |
| rDRI [n]b | 0.139 | |||
| Low risk | 1 (1.7) | 1 (2.3) | 0 | |
| Intermediate risk | 32 (54.2) | 24 (55.8) | 8 (50) | |
| High risk | 18 (30.5) | 16 (37.2) | 2 (12.5) | |
| Very high risk | 8 (13.6) | 2 (4.7) | 6 (37.5) | |
| rPAM score [score]a | 23.9 (12.1–42.1) | 22.9 (12.1–33.5) | 25 (16.4–42.1) | 0.192 |
| Acute GVHD [n]b | 0.687 | |||
| None | 29 (49.2) | 21 (48.8) | 8 (50) | |
| Grade I | 11 (18.6) | 9 (20.9) | 2 (12.5) | |
| Grade II | 6 (10.2) | 6 (14) | 0 | |
| Grade III | 11 (18.6) | 5 (11.6) | 6 (37.5) | |
| Grade IV | 2 (3.4) | 2 (4.7) | 0 | |
| Chronic GVHD [n]b | 0.022* | |||
| None | 32 (54.2) | 24 (55.8) | 8 (50) | |
| Limited | 8 (13.6) | 8 (18.6) | 0 | |
| Extensive | 11 (18.6) | 11 (25.6) | 0 | |
| Missing datae | 8 (13.6) | 0 | 8 (50) | |
| Causes of death [n]b | ||||
| Alive | 43 (72.9) | 43 (100) | 0 | |
| Relapse/progression disease | 4 (6.8) | 0 | 4 (25) | |
| Organ failure | 1 (1.7 | 0 | 1 (6.3) | |
| GVHD | 5 (8.5) | 0 | 5 (31.3) | |
| Infection | 6 (10.2) | 0 | 6 (37.5) | |
2yrsS 2-year survivor, 2yrsD 2-year decedents, HLA human leukocyte antigen, TT thiotepa, BU busulfan, FLU fludarabine, TBI total body irradiation, VP16 etoposide, BCNU camustin, MEL melphalan, TREOS treosulfan, ALL acute lymphocytic leukemia, CR complete remission, KPS Karnofsky Performance Scale, HCT-CI Hematopoietic Cell Transplantation-specific Comorbidity Index, EBMT European Society for Blood and Marrow Transplantation, rDRI revised Disease Risk Index, rPAM revised Pretransplant Assessment of Mortality, GVHD graft-versus-host disease.
aMedian (range).
bpercentage of N (%).
cIncludes: acute myeloid leukemia, chronic myeloid leukemia, chronicle myelomonocytic leukemia, osteomyelofibrosis and myelodysplastic syndrome.
dIncludes: hodgkin disease, non-hodgkin lymphoma, multiple myeloma, chronic lymphatic leukemia, acute lymphatic leukemia.
ePatients had died by the time chronic GVHD can occur (100 days after alloHCT).